

# Efficacy of Quetiapine in Parkinson's Psychosis

<b>Submission date</b> 14/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 09/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 06/10/2009	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Anthony David

### Contact details

Institute of Psychiatry  
P.O. Box 68  
De Crespigny Park  
Denmark Hill  
London  
United Kingdom  
SE5 8AF  
+44 (0)207 848 0138  
A.David@iop.kcl.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

KCL/KCH-CT2004-1

# Study information

## Scientific Title

## Acronym

EQuiPP

## Study objectives

The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised placebo controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Parkinson's disease

## Interventions

Quetiapine versus Placebo

## Intervention Type

Drug

## Phase

Not Specified

## Drug/device/biological/vaccine name(s)

Quetiapine

**Primary outcome measure**

1. Improvement in psychotic symptoms
2. Parkinsonian symptoms
3. Depressive symptoms
4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)

**Secondary outcome measures**

1. Activities of daily living
2. Cognitive function
3. Carer burden

**Overall study start date**

01/08/2005

**Completion date**

01/08/2006

**Eligibility****Key inclusion criteria**

1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

60

**Key exclusion criteria**

1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days

**Date of first enrolment**

01/08/2005

**Date of final enrolment**

01/08/2006

# Locations

## Countries of recruitment

England

United Kingdom

## Study participating centre

**Institute of Psychiatry**

London

United Kingdom

SE5 8AF

# Sponsor information

## Organisation

King's College London (UK)

## Sponsor details

c/o Gill Dale

P.O. Box 005

The Institute of Psychiatry

De Crespigny Park

Denmark Hill

London

England

United Kingdom

SE5 8AF

## Sponsor type

University/education

## Website

<http://www.iop.kcl.ac.uk>

## ROR

<https://ror.org/0220mzb33>

# Funder(s)

## Funder type

Charity

**Funder Name**

Parkinson's Disease Society (UK) (Ref: 4052)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2009		Yes	No